

CURRENT REPORT

Report date: **30.10.2026**

Name of issuing company: **Antibiotice S.A.**

Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**

<https://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

Important event to report:

Antibiotice S.A. informs its shareholders and investors that, at the request of **Mr Ioan Nani, Chief Executive Officer**, his mandate agreement will terminate on **4 December 2026**. The Board of Directors acknowledged his request at its meeting held on 29 October 2026.

Mr Ioan Nani has led the company for nearly three decades, transforming a traditional manufacturing business into a benchmark for stability and performance in the Romanian pharmaceutical industry. After a professional life devoted almost entirely to the company, his wish to spend more time with his family and loved ones is entirely natural.

Under his leadership, Antibiotice has become one of Romania's leading generic pharmaceutical manufacturers, with a portfolio spanning prescription medicines (Rx) and non-Rx products, including over-the-counter medicines, food supplements and medical devices. The company exports its products to 70 countries and holds a position as a world leader in the production of the active pharmaceutical ingredient nystatin. Beyond these figures, Antibiotice remains a strong and respected brand, supported by a highly skilled team, processes certified to international standards and an outstanding reputation in an industry with quality requirements as stringent as those of the pharmaceutical sector.

Until 4 December 2026, Mr Ioan Nani will continue to exercise his duties in full and, together with the Board of Directors, oversee the transition process. The company's activities will continue in accordance with the Administration Plan approved by shareholders. The executive team under his leadership will ensure the continuity of

day-to-day operations, relationships with partners in Romania and international markets, and ongoing investment projects.

For the period following 4 December 2026, the Board of Directors will appoint an interim Chief Executive Officer and conduct the selection process for a new Chief Executive Officer in accordance with Government Emergency Ordinance No. 109/2011 on the corporate governance of public enterprises. The General Meeting of Shareholders will also be convened to appoint an interim member of the Board of Directors and initiate the selection process for a new Board member for a full term, in compliance with all applicable legal procedures. Each decision adopted in this respect will be disclosed to the capital market through a current report.

The company's strategic objectives remain unchanged: sustainable business development, strengthening its position in the domestic market, expanding its international presence and safeguarding shareholders' long-term interests.

The Board of Directors, executive management and employees of Antibiotice express their sincere gratitude to Mr Ioan Nani for everything he has built and for leaving the company strong and ready for its next chapter. Here at Antibiotice, he is—and always will be—at home.

President of the Management Board,
Ionuț-Sebastian IAVOR